Today: 1 March 2026
Subscribe
Browse Category

NYSE:MRK 13 December 2025 - 25 December 2025

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck shares closed at $106.45 on Dec. 24, capping a six-day rally driven by a BMO Capital Markets upgrade to Outperform and a new $130 price target. Analysts cited confidence in Merck’s pipeline as it prepares for Keytruda’s 2028 loss of exclusivity. Recent gains also follow positive oncology data and a European regulatory milestone for Winrevair. U.S. markets were closed Dec. 25 for Christmas.
25 December 2025
·
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck shares hit a 52-week high near $106.50 on December 24 after a six-day, 8.3% rally. The surge followed a BMO Capital Markets upgrade to “Outperform” with a $130 target and positive late-stage trial results for Keytruda combinations in bladder cancer. European regulators advanced WINREVAIR for pulmonary hypertension. U.S. markets were closed December 25.
25 December 2025
··
Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck shares closed near $106.45 on Dec. 24, up 1.3%, hitting a new 52-week high in a shortened Christmas Eve session. The stock contributed to the Dow’s advance as U.S. markets posted record closes. Trading volume remained thin after hours. No new corporate news was released, but investors continued to react to last week’s drug-pricing agreement with the Trump administration.
24 December 2025
··
Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck shares hit a 12-month high near $106 on December 24, 2025, capping a 30% rally over three months. The surge follows a Trump administration deal requiring Merck to cut prices on drugs like Januvia for Medicaid and direct-to-consumer sales. Analysts cite optimism about Merck’s growth beyond Keytruda’s patent expiration and progress on new drugs.
24 December 2025
··
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck closed Tuesday at $105.04, up 0.3%, then slipped to about $104.81 in after-hours trading. The stock is trading near its 52-week high of $105.84 after gains tied to new White House drug-pricing agreements and FDA fast-track headlines. Merck will sell several diabetes drugs at roughly 70% off list prices under the TrumpRx plan.
24 December 2025
··
Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck shares traded near $104.68 midday Tuesday, little changed after the company joined TrumpRx drug-pricing agreements offering tariff relief in exchange for lower prices on Medicaid and some cash-pay drugs. Merck will provide Januvia and Janumet at about 70% off list price to eligible U.S. patients. Investors are weighing policy clarity and late-stage pipeline prospects as Keytruda nears loss of exclusivity.
23 December 2025
··
Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Merck announced a new U.S. drug-pricing agreement, pledging to offer Januvia and related diabetes drugs at about 70% off list prices through a direct-to-patient program. The company also reached a deal with the Commerce Department to delay Section 232 tariffs for three years. Merck shares closed at $101.09, near the top of their 52-week range. The next earnings report is expected in early February 2026.
22 December 2025
·
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck shares closed at $101.09 Friday, up 0.4%, then dipped slightly after hours as investors reacted to new U.S. drug-pricing agreements and FDA acceleration for two pipeline drugs. Trading volume surged to 43.6 million shares after the Trump administration and major pharma firms, including Merck, finalized deals to cut drug prices and grant tariff relief.
20 December 2025
··
Merck (MRK) Stock After Hours: Key News, Analyst Calls, and What to Watch Before the Dec. 19, 2025 Market Open

Merck (MRK) Stock After Hours: Key News, Analyst Calls, and What to Watch Before the Dec. 19, 2025 Market Open

Merck shares closed up 1.52% at $100.69 on Thursday, with after-hours trading showing little change. The move followed a BMO Capital Markets upgrade to Outperform and a price target hike to $130, citing confidence in Merck’s post-Keytruda growth prospects. Trading volume topped 14.2 million shares, above the 50-day average. Merck outperformed Johnson & Johnson and Pfizer on the day.
19 December 2025
·
Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck shares rose modestly Thursday after BMO Capital Markets upgraded the stock to Outperform and raised its price target to $130. The FDA is reportedly moving to fast-track two Merck pipeline drugs. Merck also announced positive Phase 3 results for Keytruda plus Padcev in earlier-stage bladder cancer, showing improved survival outcomes.
18 December 2025
··
Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck shares fell 2.21% to $98.05 Tuesday, weighing heavily on the Dow Jones Industrial Average, which dropped about 250 points. The stock traded between $96.85 and $100.49 amid broad market pressure and ongoing company-specific developments, including regulatory progress for Winrevair and efforts to defend Keytruda ahead of looming patent expirations.
16 December 2025
Merck (MRK) Stock After Hours Today (Dec. 15, 2025): What’s Moving Shares and What to Watch Before Tuesday’s Open

Merck (MRK) Stock After Hours Today (Dec. 15, 2025): What’s Moving Shares and What to Watch Before Tuesday’s Open

Merck shares closed at $100.26 on December 15 after trading between $98.00 and $100.94, with volume near 16.4 million. The ex-dividend date for Merck’s $0.85 quarterly dividend fell today, affecting price comparisons across services. Bank of America raised its price target to $120 and kept a Buy rating. In after-hours trading, MRK was little changed near $100.27.
16 December 2025
·
Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck shares traded near $99.59 Monday afternoon, down 0.23%, after Bank of America raised its price target to $120 and reiterated a Buy rating. The move followed a positive European CHMP opinion on Winrevair and a higher dividend as the stock hit its ex-dividend date. Investors weighed these developments against ongoing regulatory scrutiny and questions about Merck’s post-Keytruda strategy.
15 December 2025
··
Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck shares closed at $100.30 on Dec. 12, ahead of the Dec. 15 ex-dividend date for a $0.85 quarterly payout. The stock sits 5.2% below its 52-week high, with Friday’s volume at 11.8 million shares, under the 50-day average. Investors are watching the impact of the dividend reset and ongoing developments around Keytruda and RSV products.
14 December 2025
·
Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck shares closed at $100.30 on Friday, up 1.3% for the day and 0.6% for the week, rebounding after early losses tied to vaccine-policy headlines and RSV therapy scrutiny. The stock gained despite broad market declines. Merck received a positive EU CHMP opinion for expanded use of Winrevair, while the FDA launched new safety reviews of its RSV preventive therapies for infants.
13 December 2025
··
1 … 3 4 5 6 7
Go toTop